Concepts (151)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis C | 12 | 2022 | 179 | 4.280 |
Why?
|
| Antiviral Agents | 14 | 2021 | 498 | 4.050 |
Why?
|
| Hepatitis C, Chronic | 7 | 2020 | 94 | 2.620 |
Why?
|
| Hepacivirus | 6 | 2022 | 131 | 2.190 |
Why?
|
| Gastroenterology | 4 | 2021 | 152 | 1.250 |
Why?
|
| Lactulose | 1 | 2023 | 22 | 0.840 |
Why?
|
| Hepatic Encephalopathy | 1 | 2023 | 38 | 0.830 |
Why?
|
| Liver Diseases | 2 | 2016 | 245 | 0.750 |
Why?
|
| Ribavirin | 2 | 2013 | 40 | 0.730 |
Why?
|
| Internship and Residency | 4 | 2021 | 1085 | 0.720 |
Why?
|
| Hypereosinophilic Syndrome | 1 | 2021 | 6 | 0.710 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2021 | 19 | 0.710 |
Why?
|
| Off-Label Use | 2 | 2014 | 16 | 0.530 |
Why?
|
| Health Services Accessibility | 3 | 2017 | 452 | 0.500 |
Why?
|
| Interferon-alpha | 2 | 2013 | 213 | 0.480 |
Why?
|
| Hepatitis B, Chronic | 1 | 2015 | 33 | 0.470 |
Why?
|
| Informed Consent | 2 | 2020 | 278 | 0.460 |
Why?
|
| Viral Load | 2 | 2021 | 147 | 0.440 |
Why?
|
| Medicaid | 1 | 2017 | 248 | 0.430 |
Why?
|
| Polyethylene Glycols | 2 | 2013 | 361 | 0.430 |
Why?
|
| Interferons | 1 | 2014 | 128 | 0.420 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2015 | 236 | 0.380 |
Why?
|
| Liver Transplantation | 4 | 2023 | 1186 | 0.380 |
Why?
|
| Drug Discovery | 1 | 2013 | 110 | 0.370 |
Why?
|
| Humans | 29 | 2023 | 92331 | 0.360 |
Why?
|
| Biliary Tract Diseases | 1 | 2011 | 36 | 0.350 |
Why?
|
| Resource Allocation | 1 | 2011 | 65 | 0.350 |
Why?
|
| Curriculum | 4 | 2021 | 583 | 0.350 |
Why?
|
| Health Care Rationing | 1 | 2011 | 84 | 0.340 |
Why?
|
| Patient Participation | 1 | 2012 | 227 | 0.340 |
Why?
|
| Treatment Outcome | 8 | 2021 | 8730 | 0.310 |
Why?
|
| Liver Cirrhosis | 3 | 2016 | 269 | 0.300 |
Why?
|
| Tissue and Organ Procurement | 1 | 2010 | 380 | 0.230 |
Why?
|
| United States | 7 | 2021 | 7360 | 0.230 |
Why?
|
| Healthcare Disparities | 2 | 2021 | 443 | 0.220 |
Why?
|
| Proline | 2 | 2013 | 55 | 0.190 |
Why?
|
| Social Stigma | 1 | 2022 | 76 | 0.190 |
Why?
|
| Vulnerable Populations | 1 | 2022 | 84 | 0.190 |
Why?
|
| United States Food and Drug Administration | 2 | 2014 | 137 | 0.190 |
Why?
|
| Viremia | 1 | 2021 | 49 | 0.180 |
Why?
|
| Oligopeptides | 2 | 2013 | 190 | 0.170 |
Why?
|
| Azathioprine | 1 | 2021 | 124 | 0.170 |
Why?
|
| Donor Selection | 1 | 2021 | 79 | 0.170 |
Why?
|
| Prednisone | 1 | 2021 | 254 | 0.170 |
Why?
|
| Beneficence | 1 | 2020 | 35 | 0.170 |
Why?
|
| Risk Assessment | 4 | 2021 | 2368 | 0.160 |
Why?
|
| Drug Therapy, Combination | 2 | 2014 | 806 | 0.160 |
Why?
|
| Recombinant Proteins | 2 | 2013 | 1016 | 0.160 |
Why?
|
| Immunoglobulin G | 1 | 2021 | 460 | 0.150 |
Why?
|
| Glucocorticoids | 1 | 2021 | 367 | 0.150 |
Why?
|
| Ethics, Medical | 1 | 2021 | 308 | 0.150 |
Why?
|
| Anti-Bacterial Agents | 1 | 2023 | 808 | 0.140 |
Why?
|
| Tissue Donors | 1 | 2021 | 531 | 0.140 |
Why?
|
| Female | 10 | 2021 | 47895 | 0.140 |
Why?
|
| Legislation, Drug | 1 | 2017 | 6 | 0.140 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2023 | 556 | 0.130 |
Why?
|
| Paracentesis | 1 | 2016 | 9 | 0.130 |
Why?
|
| Coinfection | 2 | 2015 | 63 | 0.130 |
Why?
|
| Flaviviridae Infections | 1 | 2015 | 1 | 0.120 |
Why?
|
| GB virus C | 1 | 2015 | 1 | 0.120 |
Why?
|
| Ascites | 1 | 2016 | 57 | 0.120 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 989 | 0.120 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2015 | 22 | 0.120 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2021 | 617 | 0.120 |
Why?
|
| Internal Medicine | 2 | 2016 | 366 | 0.120 |
Why?
|
| Deficiency Diseases | 1 | 2015 | 12 | 0.120 |
Why?
|
| Career Choice | 1 | 2016 | 153 | 0.120 |
Why?
|
| Comorbidity | 2 | 2015 | 986 | 0.110 |
Why?
|
| Liver Failure | 1 | 2015 | 69 | 0.110 |
Why?
|
| Zinc | 1 | 2015 | 100 | 0.110 |
Why?
|
| Drug and Narcotic Control | 1 | 2014 | 7 | 0.110 |
Why?
|
| Time Factors | 4 | 2021 | 5430 | 0.110 |
Why?
|
| Protease Inhibitors | 1 | 2014 | 72 | 0.110 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2014 | 37 | 0.110 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 867 | 0.110 |
Why?
|
| Liver Neoplasms | 1 | 2020 | 764 | 0.110 |
Why?
|
| Drug Design | 1 | 2014 | 130 | 0.110 |
Why?
|
| Middle Aged | 6 | 2021 | 27043 | 0.110 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2014 | 78 | 0.100 |
Why?
|
| Drug Industry | 1 | 2014 | 54 | 0.100 |
Why?
|
| Male | 8 | 2021 | 43923 | 0.100 |
Why?
|
| Hepatitis B | 1 | 2014 | 79 | 0.100 |
Why?
|
| Chronic Disease | 1 | 2016 | 966 | 0.100 |
Why?
|
| Disease Management | 1 | 2015 | 341 | 0.100 |
Why?
|
| Algorithms | 2 | 2020 | 1960 | 0.090 |
Why?
|
| Truth Disclosure | 1 | 2012 | 92 | 0.090 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 291 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 1938 | 0.090 |
Why?
|
| Physicians | 1 | 2018 | 693 | 0.090 |
Why?
|
| Education, Medical, Graduate | 1 | 2015 | 412 | 0.090 |
Why?
|
| Clinical Competence | 1 | 2016 | 808 | 0.090 |
Why?
|
| Recurrence | 1 | 2013 | 1180 | 0.080 |
Why?
|
| Hospitalization | 1 | 2016 | 925 | 0.080 |
Why?
|
| Cohort Studies | 2 | 2015 | 2979 | 0.080 |
Why?
|
| Animals | 2 | 2023 | 28061 | 0.080 |
Why?
|
| Postoperative Period | 1 | 2011 | 311 | 0.080 |
Why?
|
| Decision Trees | 1 | 2020 | 62 | 0.080 |
Why?
|
| Mice | 1 | 2023 | 12133 | 0.080 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 1920 | 0.080 |
Why?
|
| Precision Medicine | 1 | 2013 | 425 | 0.080 |
Why?
|
| Age Factors | 1 | 2013 | 1904 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 1072 | 0.070 |
Why?
|
| Critical Illness | 1 | 2011 | 327 | 0.070 |
Why?
|
| Prognosis | 1 | 2015 | 3871 | 0.070 |
Why?
|
| Critical Care | 1 | 2011 | 397 | 0.070 |
Why?
|
| Physician-Patient Relations | 1 | 2012 | 630 | 0.070 |
Why?
|
| Aged, 80 and over | 2 | 2015 | 6917 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2009 | 542 | 0.060 |
Why?
|
| Databases, Factual | 2 | 2021 | 955 | 0.060 |
Why?
|
| Mass Screening | 2 | 2022 | 675 | 0.060 |
Why?
|
| Aged | 4 | 2016 | 19951 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2009 | 1150 | 0.050 |
Why?
|
| HIV Infections | 1 | 2013 | 896 | 0.050 |
Why?
|
| Fatty Acids | 1 | 2023 | 149 | 0.050 |
Why?
|
| Dysbiosis | 1 | 2023 | 89 | 0.050 |
Why?
|
| Feces | 1 | 2023 | 349 | 0.050 |
Why?
|
| Risk Factors | 3 | 2021 | 5708 | 0.050 |
Why?
|
| Adult | 3 | 2021 | 27540 | 0.050 |
Why?
|
| Colorectal Neoplasms | 1 | 2009 | 1042 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2021 | 299 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 290 | 0.040 |
Why?
|
| Chicago | 1 | 2022 | 1463 | 0.040 |
Why?
|
| Graft Survival | 1 | 2021 | 935 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2021 | 474 | 0.030 |
Why?
|
| Cost Savings | 1 | 2016 | 71 | 0.030 |
Why?
|
| Hospital Costs | 1 | 2016 | 114 | 0.030 |
Why?
|
| Hospitals, University | 1 | 2015 | 197 | 0.030 |
Why?
|
| Quality Indicators, Health Care | 1 | 2016 | 152 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 289 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2015 | 305 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2015 | 130 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2015 | 159 | 0.030 |
Why?
|
| Linear Models | 1 | 2015 | 427 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 887 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2016 | 488 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2016 | 445 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 863 | 0.020 |
Why?
|
| Length of Stay | 1 | 2016 | 790 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 995 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2015 | 499 | 0.020 |
Why?
|
| Base Sequence | 1 | 2015 | 2324 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 3023 | 0.020 |
Why?
|
| Survival Rate | 1 | 2015 | 1926 | 0.020 |
Why?
|
| Disease Progression | 1 | 2015 | 1500 | 0.020 |
Why?
|
| Phylogeny | 1 | 2015 | 1230 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 2685 | 0.020 |
Why?
|
| Family Health | 1 | 2009 | 158 | 0.020 |
Why?
|
| Health Education | 1 | 2009 | 105 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 3776 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2015 | 9693 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2009 | 2397 | 0.010 |
Why?
|